Anti-Cdc13 antibody [6F11/2] (ab10873)
Key features and details
- Mouse monoclonal [6F11/2] to Cdc13
- Suitable for: WB, IP
- Isotype: IgG2a
Overview
-
Product name
Anti-Cdc13 antibody [6F11/2] -
Description
Mouse monoclonal [6F11/2] to Cdc13 -
Host species
Mouse -
Tested applications
Suitable for: WB, IPmore details -
Immunogen
Full length native protein (purified).
-
General notes
Cdc13 is a fission yeast (S. pombe) B-type M-phase cyclin. Cdc13 binds to Cdk1 (cdc2), and the resulting Cdk1-Cdc13 complex controls the G2/M transition of the cell cycle. 6F11/2 can be used for detecting Cdc13 and associated Cdk1 kinase activation.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.
One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.
Learn more here.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
Constituent: PBS -
Concentration information loading... -
Purity
Protein A purified -
Primary antibody notes
Cdc13 is a fission yeast (S. pombe) B-type M-phase cyclin. Cdc13 binds to Cdk1 (cdc2), and the resulting Cdk1-Cdc13 complex controls the G2/M transition of the cell cycle. 6F11/2 can be used for detecting Cdc13 and associated Cdk1 kinase activation. -
Clonality
Monoclonal -
Clone number
6F11/2 -
Myeloma
Sp2 -
Isotype
IgG2a -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab10873 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB |
Use at an assay dependent dilution. Predicted molecular weight: 48 kDa.
|
|
| IP |
Use at an assay dependent dilution.
|
| Notes |
|---|
|
WB
Use at an assay dependent dilution. Predicted molecular weight: 48 kDa. |
|
IP
Use at an assay dependent dilution. |
Target
-
Alternative names
- CDC 13 antibody
- G2/mitotic specific cyclin antibody
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (5)
ab10873 has been referenced in 5 publications.
- Rothe C et al. A checkpoint-independent mechanism delays entry into mitosis after UV irradiation. J Cell Sci 130:4028-4037 (2017). PubMed: 29046339
- Uchiyama M et al. The Protein Level of Rev1, a TLS Polymerase in Fission Yeast, Is Strictly Regulated during the Cell Cycle and after DNA Damage. PLoS One 10:e0130000 (2015). PubMed: 26147350
- Bandyopadhyay S et al. The basic leucine zipper domain transcription factor Atf1 directly controls Cdc13 expression and regulates mitotic entry independently of Wee1 and Cdc25 in Schizosaccharomyces pombe. Eukaryot Cell 13:813-21 (2014). Schizosaccharomyces pombe . PubMed: 24728197
- Okuzaki D et al. Spo5 phosphorylation is essential for its own timely degradation and for successful meiosis in Schizosaccharomyces pombe. Cell Cycle 9: (2010). WB ; Schizosaccharomyces pombe . PubMed: 20855961
- Decottignies A et al. In vivo localisation of fission yeast cyclin-dependent kinase cdc2p and cyclin B cdc13p during mitosis and meiosis. J Cell Sci 114:2627-40 (2001). PubMed: 11683390